Tapering Antidepressants

Introduction to Tapering

Mirtazapine 7.5mg can be initiated for sleep and mood, helping with insomnia and anxiety during withdrawal, as supported by the Mayo Clinic Proceedings 1
Trazodone is recommended for short-term use during SNRI tapering, helping manage anxiety, insomnia, and irritability during withdrawal, with a lower incidence of weight gain compared to mirtazapine and less anticholinergic activity than other options 1

Mirtazapine is effective for managing anxiety symptoms during tapering, as per the Mayo Clinic Proceedings 1
Trazodone can be used as an alternative to mirtazapine due to its effectiveness in managing withdrawal symptoms with fewer side effects, as recommended by the Mayo Clinic Proceedings 1
Low-dose doxepin could be considered as an alternative to mirtazapine, according to the American Academy of Sleep Medicine 2

A gradual reduction of 10% per month is recommended for patients on long-term therapy, with the option to increase to 10% per week until reaching 30% of the original dose, then slowing to 10% weekly reductions, as suggested by the Mayo Clinic Proceedings 1
A sample tapering schedule is provided:

Hydroxyzine pamoate (25mg morning/afternoon and 50mg bedtime) is effective for managing anxiety symptoms during tapering 1
Propranolol 10mg BID PRN is helpful for physical symptoms of withdrawal like tachycardia or tremor 1
Methylphenidate ER 20mg may help with fatigue or low energy during withdrawal 1
Bupropion XL 150mg provides noradrenergic effects that can help offset SNRI withdrawal 1
Gabapentin is effective for managing withdrawal symptoms, with no known drug interactions with desvenlafaxine, and is particularly helpful for physical symptoms like pain and paresthesias, with the option to be used short-term without tapering concerns 1
α2-agonists, such as clonidine, tizanidine, and lofexidine, can be used to directly attenuate withdrawal symptoms, with clonidine requiring careful dosing due to potential hypotension, tizanidine having a lower risk of hypotension, and lofexidine being FDA-approved for opioid withdrawal symptoms 1
Tricyclic antidepressants (low dose) can mitigate withdrawal symptoms, but have a higher side effect profile than first-line options and should be used cautiously in patients with cardiac concerns 1
Buprenorphine (off-label) may be considered in severe cases with significant withdrawal symptoms, requiring specialized knowledge for appropriate dosing 1

Schedule follow-up visits every 2-4 weeks during the taper to assess for withdrawal symptoms 1
Patients should be assessed for withdrawal symptoms, including dizziness, headache, nausea, irritability, and paresthesias, with the taper rate adjusted based on symptom severity 1
If withdrawal symptoms become severe, temporarily pause the taper, return to the previous well-tolerated dose, and resume tapering at a slower rate after symptoms stabilize 1

Distinguish between withdrawal symptoms (typically emerge within days of dose reduction and are somatic) and depression recurrence (gradual onset, primarily mood symptoms) 1

Explain the withdrawal process and normalize expected symptoms 1
Adjunctive medication, such as trazodone, should be begun 1-2 weeks before starting the taper and continued throughout the tapering process and 2-4 weeks after completing the taper 1

Tapering too quickly is the most common cause of withdrawal symptoms and discontinuation failure, with the importance of overlooking drug interactions, ignoring breakthrough symptoms, discontinuing adjunctive medication too soon, and failing to distinguish between withdrawal symptoms and depression recurrence 1
Gabapentin may require dose adjustment based on renal function, and sedating medications that increase fall risk should be avoided, with consideration of a slower tapering schedule (e.g., 5% reductions monthly) 3